Rising Demand: Hepatocellular Carcinoma (HCC) Market Predicted to...

Rising Demand: Hepatocellular Carcinoma (HCC) Market Predicted to Expand at 10.20% CAGR by 2027

Δημοσιευμένα 2024-10-17 09:50:28

2χλμ.

A comprehensive analysis report on the Global Hepatocellular Carcinoma (HCC) Market has been recently released by MarkNtel Advisors, covering the forecast period from 2022 to 2027. The expert team of analysts dedicated significant effort to gathering and evaluating the latest market data, resulting in a detailed and up-to-date report that offers valuable insights for individuals who rely on data-driven decisions, including business owners and analysts. The research report on the Hepatocellular Carcinoma (HCC) Market presents well-researched facts and figures pertinent to the industry, whether the goal is to explore new markets, launch a new product, or maintain a competitive advantage.

Hepatocellular Carcinoma (HCC) Market Overview:

Base Year: 2021

Forecast Years: 2022-2027

Historical Years: 2017-2020

Market Growth Rate: 10.20% (2022-2027)

“In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecasts for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn't take long for the team to deliver the most recent version of the report.”

Request For a Free PDF Sample of the Report – https://www.marknteladvisors.com/query/request-sample/hepatocellular-carcinoma-hcc-market.html

Hepatocellular Carcinoma (HCC) Market Segmentation Analysis:

According to MarkNtel study the market is segmented the into the following categories:

By Diagnosis

Blood Tests
- AFP (Alfa-Fetoprotein)
- LFT (Liver Function Test)
Hepatic Angiography
Liver Biopsy
Laparoscopy
Others (MRI, CT scan, etc.)

Of all HCC diagnoses, blood tests are the most commonly used laboratory tests owing to their accuracy & cost-efficiency.

By Treatment

Chemotherapy
- Cisplatin
- Gemcitabine (Gemzar)
- Oxaliplatin (Eloxatin)
- Doxorubicin (pegylated liposomal doxorubicin)
- 5-fluorouracil (5-FU)
Immunotherapy
- Atezolizumab (Tecentriq)
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Ipilimumab (Yervoy)
Surgery
- Hepatectomy
- Liver Transplant
Radiation Therapy
Targeted Therapy
- Kinase Inhibitors
  - Sorafenib
  - Lenvatinib
  - Regorafenib (Stivarga)
  - Cabozantinib (Cabometyx)
- Monoclonal Antibodies
  - Bevacizumab (Avastin)
  - Ramucirumab (Cyramza)

By End-User

Hospitals
Cancer Centers
Others (Ambulatory Surgery Centers, etc.)

Browse Full Report With TOC and Latest Market Scope - https://www.marknteladvisors.com/research-library/hepatocellular-carcinoma-hcc-market.html

By Region

North America
South America
Europe
Middle East & Africa
Asia-Pacific

Of all regions globally, North America holds a significant share in the Hepatocellular Carcinoma (HCC) Market.

Hepatocellular Carcinoma (HCC) Market Competitive Landscape:

This section competitive landscape covers the top companies’ participants in the Hepatocellular Carcinoma (HCC) industry, and their business description, product portfolio, strategic alliances or partnerships, recent developments, financial details analysis from 2022-2027.

Leading Market Player Are:

Amgen Inc.
AstraZeneca plc
Bayer AG
BeiGene
Bristol Myers Squibb
Eisai Co., Ltd.
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request Customization - https://www.marknteladvisors.com/query/request-customization/hepatocellular-carcinoma-hcc-market.html

Key Report Highlights

Market Dimensions & Projections
Pricing Evaluation,
Recent Strategic Moves by Companies,
Primary Stakeholders,
Analysis of Import and Export Trends,
Competitive Landscape Assessment,
Emerging Opportunities,
Market Trends and Indicators

About Us:

We are a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.